Search

Bedaquiline

[A261856] Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] … [A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market.

Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)

Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) is a vaccine that is used in the prophylaxis of Pertussis (whooping cough), which is caused by a small Gram-negative coccobacillus

Vanadium

Basiliximab

It is a 144 kDa glycoprotein obtained from fermentation of an established mouse myeloma cell line genetically engineered to express plasmids containing the human heavy and light chain constant region genes … A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also

Quetiapine

Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. … It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].[A2189]

Ruxolitinib

[A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in … In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.

Podophyllin

Podophyllin is the principal active component. Podophyllin arrests mitosis in metaphase. … Podophyllin is a resin extracted from the roots of _Podophyllum peltatum_ (American mandrake) and _Podophyllum emodi_, which contains numerous compounds, amongst which is podophyllin (as well as the drug

Dibotermin alfa

Dibotermin alfa is a recombinant human bone morphogenetic protein-2 (rhBMP-2) derived from a recombinant Chinese Hamster Ovary (CHO) cell line [FDA Label]. … It is implanted in patients undergoing bone surgeries or those with fractures.

Eliglustat

[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs.

Brilliant blue G

Brilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures. … It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830]